Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024).
Kris, M. G. et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311, 1998 (2014).
Meyer, M.-L. et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet 404, 803–822 (2024).
Tan, A. C. & Tan, D. S. W. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J. Clin. Oncol. 40, 611–625 (2022).
Drusbosky, L. M., Dawar, R., Rodriguez, E. & Ikpeazu, C. V. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer. J. Hematol. Oncol. 14, 129 (2021).
Bria, E. et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann. Oncol. 22, 2277–2285 (2011).
Herbst, R. S. et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J. Clin. Oncol. 41, 1830–1840 (2023).
Zhong, W.-Z. et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J. Clin. Oncol. 39, 713–722 (2021).
Zhong, W.-Z. et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal Transduct. Target. Ther. 8, 76 (2023).
Wu, Y.-L. et al. Alectinib in resected ALK -positive non–small-cell lung cancer. N. Engl. J. Med. 390, 1265–1276 (2024).
Zenke, Y. et al. P1.18-04 neoadjuvant ceritinib for locally advanced non-small cell lung cancer with ALK rearrangement: SAKULA trial. J. Thorac. Oncol. 14, S626–S627 (2019).
Miyoshi, T. & Tsuboi, M. Postoperative adjuvant therapy with molecularly targeted agents for non-small cell lung cancer. Int. J. Clin. Oncol. 30, 210–214 (2025).
Akamatsu, H. Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced NSCLC with EGFR mutation; West Japan Oncology Group 6911L. J. Thorac. Oncol. 16, 1745–1752 (2021).
Hotta, K. et al. Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study. ESMO Open 6, 100191 (2021).
Bai, X. et al. Structure and dynamics of the EGFR/HER2 heterodimer. Cell Discov. 9, 18 (2023).
Liu, R. et al. Monoglyceride lipase gene knockout in mice leads to increased incidence of lung adenocarcinoma. Cell Death Dis. 9, 36 (2018).
Wu, Y.-L. et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 18, 1454–1466 (2017).
Rangachari, D. et al. Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers. Lung Cancer 88, 108–111 (2015).
Offin, M. et al. Frequency and outcomes of brain metastases in patients with HER2 -mutant lung cancers. Cancer 125, 4380–4387 (2019).
Patil, T. et al. The incidence of brain metastases in stage IV ROS1-rearranged non–small cell lung cancer and rate of central nervous system progression on crizotinib. J. Thorac. Oncol. 13, 1717–1726 (2018).
Long, J. et al. Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study. Ann. Transl. Med. 10, 1334 (2022).
Shi, Y. K. et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann. Oncol. 28, 2443–2450 (2017).
Wu, Y.-L. et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 15, 213–222 (2014).
Wu, Y.-L. et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non–small-cell lung cancer: data from a randomized phase III trial (AURA3). J. Clin. Oncol. 36, 2702–2709 (2018).
Mok, T. S. et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N. Engl. J. Med. 376, 629–640 (2017).
Papadimitrakopoulou, V. A. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann. Oncol. 31, 1536–1544 (2020).
Majem, M. et al. First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. Eur. J. Cancer 159, 174–181 (2021).
Reungwetwattana, T. et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR -mutated advanced non–small-cell lung cancer. J. Clin. Oncol. 36, 3290–3297 (2018).
Soria, J.-C. et al. Osimertinib in untreated EGFR -mutated advanced non–small-cell lung cancer. N. Engl. J. Med. 378, 113–125 (2018).
Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR -mutated advanced NSCLC. N. Engl. J. Med. 382, 41–50 (2020).
Leighl, N. B. et al. Patient-reported outcomes from FLAURA: osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. Eur. J. Cancer 125, 49–57 (2020).
Lu, S. et al. Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial. J. Thorac. Oncol. 17, 411–422 (2022).
Lu, S. et al. Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS). J. Clin. Oncol. 40, 9096 (2022).
Lu, S. et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon–small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations. J. Clin. Oncol. 40, 3162–3171 (2022).
Yun, J. et al. YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non–small cell lung cancer. Clin. Cancer Res. 25, 2575–2587 (2019).
Cho, B. C. et al. Lazertinib versus gefitinib as first-line treatment in patients with EGFR -mutated advanced non–small-cell lung cancer: results from LASER301. J. Clin. Oncol. 41, 4208–4217 (2023).
Soo, R. A. et al. Central nervous system outcomes of lazertinib versus gefitinib in EGFR-mutated advanced NSCLC: a LASER301 subset analysis. J. Thorac. Oncol. 18, 1756–1766 (2023).
Cho, B. C. et al. A Phase 1/2 study of lazertinib 240 mg in patients with advanced EGFR T790M-positive NSCLC after previous EGFR tyrosine kinase inhibitors. J. Thorac. Oncol. 17, 558–567 (2022).
Jang, S. B. et al. Cardiac safety assessment of lazertinib: findings from patients with EGFR mutation-positive advanced NSCLC and preclinical studies. JTO Clin. Res. Rep. 2, 100224 (2021).
Shi, Y. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respir. Med. 9, 829–839 (2021).
Shi, Y. et al. Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR-mutated NSCLC: results from the FURLONG study. J. Thorac. Oncol. 17, 1297–1305 (2022).
Shi, Y. et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir. Med. 10, 1019–1028 (2022).
Ahn, M.-J. et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir. Med. 5, 891–902 (2017).
Zhou, Q. et al. First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: the phase 3 EVEREST trial. Med 6, 100513 (2025).
Maggie Liu, S.-Y. et al. Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial. eClinicalMedicine 64, 102238 (2023).
Lu, S. et al. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. Lancet Respir. Med. 11, 905–915 (2023).
Lu, S. et al. LBA9 Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Ann. Oncol. 34, S1654 (2023).
Lu, S. et al. Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M-mutated NSCLC that had progressed after prior EGFR tyrosine kinase inhibitor therapy: a phase 2, multicenter, single-arm, open-label study. J. Thorac. Oncol. 17, 1192–1204 (2022).
Shi, Y. et al. Efficacy and Safety of Limertinib (ASK120067) in patients with locally advanced or metastatic EGFR Thr790Met-mutated NSCLC: a multicenter, single-arm, phase 2b study. J. Thorac. Oncol. 17, 1205–1215 (2022).
Shi, Y. et al. Efficacy and safety of rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC: a phase 2b study. J. Thorac. Oncol. 17, 1306–1317 (2022).
Shi, Y. et al. Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study. Lancet Respir. Med. 13, 327–337 (2025).
Zhou, C. & Xiong, A. OA02.04 A phase III study of rilertinib versus gefitinib as first-line therapy for patients with locally advanced or metastatic EGFR-mutated NSCLC. J. Thorac. Oncol. 19, S11 (2024).
Wang, S., Tsui, S. T., Liu, C., Song, Y. & Liu, D. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. J. Hematol. Oncol. 9, 59 (2016).
Lu, X. et al. Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry. Med. Res. Rev. 38, 1550–1581 (2018).
Elamin, Y. Y. et al. BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study. J. Clin. Oncol. 41, 9011 (2023).
Lim, S. M. et al. BBT-176, a novel fourth-generation tyrosine kinase inhibitor for osimertinib-resistant EGFR mutations in non–small cell lung cancer. Clin. Cancer Res. 29, 3004–3016 (2023).
Zhou, C. et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR Exon 20 insertion–positive metastatic non–small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 7, e214761 (2021).
Wang, M. et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir. Med. 12, 217–224 (2024).
Han, B. et al. OA03.04 A phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR exon 20 insertions. J. Thorac. Oncol. 18, S49 (2023).
Yu, H. A. et al. Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab. J. Clin. Oncol. 43, 8503 (2025).
Jänne, P. A. et al. First-line mobocertinib versus platinum-based chemotherapy in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer in the phase III EXCLAIM-2 trial. J. Clin. Oncol. 43, 1553–1563 (2025).
Elamin, Y. Y. et al. Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 40, 754–767.e6 (2022).
Piotrowska, Z. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. Ann. Oncol. 29, 2092–2097 (2018).
Liu, S. V. et al. LBA61 First analysis of RAIN-701: study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions. Ann. Oncol. 31, S1189 (2020).
Yang, J. C.-H. et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 16, 830–838 (2015).
Sato, Y. et al. Survival outcomes and subgroup analyses derived from a phase III randomized trial comparing afatinib to chemotherapy in treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG1834). J. Clin. Oncol. 42, 8588 (2024).
Cho, J. H. et al. Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J. Clin. Oncol. 38, 488–495 (2020).
Borgeaud, M. et al. Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review. J. Thorac. Oncol. 19, 973–983 (2024).
Fang, W. F. et al. 57P: safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring 20ins and uncommon EGFR mutations (AIM). J. Thorac. Oncol. 20, S45–S46 (2025).
Robichaux, J. P. et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 597, 732–737 (2021).
Wells, L. & Qin, A. Treatment of non-small cell lung cancer with atypical EGFR mutations. Curr. Treat. Options Oncol. 24, 1802–1814 (2023).
Le, X. et al. PL04.07 FURTHER: a global, randomized study of firmonertinib at two dose levels in TKI-naive, advanced NSCLC with EGFR PACC mutations. J. Thorac. Oncol. 19, S5–S6 (2024).
Brazel, D. & Nagasaka, M. The development of amivantamab for the treatment of non-small cell lung cancer. Respir. Res. 24, 256 (2023).
Cho, B. C. et al. Amivantamab plus lazertinib in previously untreated EGFR -mutated advanced NSCLC. N. Engl. J. Med. 391, 1486–1498 (2024).
Zhou, C. et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N. Engl. J. Med. 389, 2039–2051 (2023).
Wang, J. et al. Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 42, 8604 (2024).
Cappuzzo, F. et al. 516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC). Ann. Oncol. 34, S1671 (2023).
Planchard, D. et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N. Engl. J. Med. 389, 1935–1948 (2023).
Jänne, P. A. et al. CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor–mutated advanced non–small-cell lung cancer. J. Clin. Oncol. 42, 808–820 (2024).
Tanaka, K. et al. Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: an open-label, randomised phase 2 clinical trial. Eur. J. Cancer 149, 14–22 (2021).
Lu, S. et al. Abstract CT053: Aumolertinib with or without chemotherapy as first line treatment in locally advanced or metastatic NSCLC with sensitizing EGFR mutations (AENEAS2). Cancer Res. 85, CT053 (2025).
Passaro, A. et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann. Oncol. 35, 77–90 (2024).
Bauml, J. et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. J. Clin. Oncol. 39, 9006 (2021).
Zhao, S. et al. Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer. Nat. Commun. 14, 3468 (2023).
Gettinger, S. et al. Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC. J. Thorac. Oncol. 13, 1363–1372 (2018).
Oxnard, G. R. et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann. Oncol. 31, 507–516 (2020).
Alexander, M. et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: patient satisfaction and resource utilization results from the PALOMA-3 study. Eur. J. Cancer 227, 115624 (2025).
Mayer, C. et al. Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms. Mod. Pathol. 35, 1882–1887 (2022).
Horn, L. et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase−positive non–small cell lung cancer: a randomized clinical trial. JAMA Oncol. 7, 1617 (2021).
Costa, D. B. et al. Clinical experience with crizotinib in patients with advanced ALK -rearranged non–small-cell lung cancer and brain metastases. J. Clin. Oncol. 33, 1881–1888 (2015).
Shaw, A. T. et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 18, 874–886 (2017).
Wolf, J. et al. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. ESMO Open 7, 100333 (2022).
Yang, J. C.-H. et al. Brigatinib versus alectinib in ALK-positive NSCLC after disease progression on crizotinib: results of phase 3 ALTA-3 trial. J. Thorac. Oncol. 18, 1743–1755 (2023).
Yang, Y. et al. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. Lancet Respir. Med. 8, 45–53 (2020).
Peters, S. et al. Alectinib versus crizotinib in untreated ALK -positive non–small-cell lung cancer. N. Engl. J. Med. 377, 829–838 (2017).
Camidge, D. R. et al. Brigatinib versus crizotinib in ALK inhibitor–naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J. Thorac. Oncol. 16, 2091–2108 (2021).
Soria, J.-C. et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 389, 917–929 (2017).
Mok, T. et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann. Oncol. 31, 1056–1064 (2020).
Shi, Y. et al. Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive NSCLC: interim analysis of a randomized, open-label, phase 3 study (INSPIRE). J. Thorac. Oncol. 19, 912–927 (2024).
Shi, Y.-K. et al. 1278P Update of the INSPIRE study: iruplinalkib versus crizotinib in ALK TKI-naïve locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC). Ann. Oncol. 35, S815 (2024).
Shi, Y. et al. Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT). BMC Med. 21, 72 (2023).
Shi, Y. et al. P1.12B.07 iruplinalkib in patients with ALK-positive crizotinib-resistant NSCLC: updated efficacy and safety data from a phase 2 trial. J. Thorac. Oncol. 19, S203 (2024).
Yang, Y. et al. Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial. Signal Transduct. Target. Ther. 8, 301 (2023).
Xiong, A. et al. OA09.03 Randomized, open-label, phase III study of SAF-189s versus crizotinib in first-line ALK-positive advanced non-small cell lung cancer (NSCLC). J. Thorac. Oncol. 19, S27–S28 (2024).
Han, B. et al. P2.01-31 preliminary results of second generation ALK inhibitor PLB1003: a phase La study. J. Thorac. Oncol. 14, S651 (2019).
Xing, P. et al. Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study. BMC Med. 20, 453 (2022).
Zou, H. Y. et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc. Natl. Acad. Sci. 112, 3493–3498 (2015).
Solomon, B. J. et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 19, 1654–1667 (2018).
Solomon, B. J. et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non–small cell lung cancer: 5-year outcomes from the phase III CROWN study. J. Clin. Oncol. 42, 3400–3409 (2024).
Liu, D. et al. Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann. Oncol. 31, 1207–1215 (2020).
Lin, J. J. et al. NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations. Cancer Discov. 14, 2367–2386 (2024).
Solomon, B. J., Millward, M., Kim, D.-W., Park, E. K. & Lin, J. J. 1363TiP A phase I/II study of TPX-0131, a novel oral ALK tyrosine kinase inhibitor, in patients with ALK+ advanced/metastatic NSCLC. Ann. Oncol. 32, S1034 (2021).
Johnson, M. L. et al. 81TiP NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study. J. Thorac. Oncol. 18, S86–S87 (2023).
Drilon, A. E. et al. 1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours. Ann. Oncol. 35, S802–S803 (2024).
Cheng, Y., Yang, J., Wang, D. & Yan, D. ROS1 fusion lung adenosquamous carcinoma patient with short-term clinical benefit after crizotinib treatment: a case report. Ann. Transl. Med. 10, 157 (2022).
Shaw, A. T. et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann. Oncol. 30, 1121–1126 (2019).
Drilon, A. et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet Oncol. 21, 261–270 (2020).
Drilon, A. et al. Long-term efficacy and safety of entrectinib in ROS1 fusion–positive NSCLC. JTO Clin. Res. Rep. 3, 100332 (2022).
Peters, S. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial. Nat. Med. 30, 1923–1932 (2024).
Lim, S. M. et al. Open-label, multicenter, phase II study of ceritinib in patients with non–small-cell lung cancer harboring ROS1 rearrangement. J. Clin. Oncol. 35, 2613–2618 (2017).
Yang, J.-J. et al. Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study. Lancet Respir. Med. 12, 671–680 (2024).
Niho, S. et al. Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study. ESMO Open 9, 103642 (2024).
Guo, R. et al. P1.14-50 a phase 2 trial of cabozantinib in ROS1-rearranged lung adenocarcinoma. J. Thorac. Oncol. 14, S574–S575 (2019).
Girard, N. et al. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study. ESMO Open 7, 100418 (2022).
Shaw, A. T. et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol. 20, 1691–1701 (2019).
Ahn, B. C. et al. Lorlatinib in TKI naïve, advanced ROS1-positive non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 trial. J. Clin. Oncol. 42, 8519 (2024).
Pérol, M. et al. Taletrectinib in ROS1 + non–small cell lung cancer: TRUST. J. Clin. Oncol. 43, 1920–1929 (2025).
Drilon, A. et al. Repotrectinib in ROS1 fusion–positive non–small-cell lung cancer. N. Engl. J. Med. 390, 118–131 (2024).
Drilon, A. et al. NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer Discov. 13, 598–615 (2023).
Drilon, A. et al. Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors. Eur. J. Cancer 174, S6–S7 (2022).
Lu, S. et al. MA06.04 unecritinib in patients with ROS1 positive advanced non-small cell lung cancer: updated results from a phase II trial. J. Thorac. Oncol. 19, S73–S74 (2024).
Ahn, H. K. et al. MET receptor tyrosine kinase regulates the expression of co-stimulatory and co-inhibitory molecules in tumor cells and contributes to PD-L1-mediated suppression of immune cell function. Int. J. Mol. Sci. 20, 4287 (2019).
Wolf, J. et al. Capmatinib in MET Exon 14–mutated or MET -amplified non–small-cell lung cancer. N. Engl. J. Med. 383, 944–957 (2020).
Seto, T. et al. Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET -amplified advanced NSCLC: GEOMETRY mono-1 study. Cancer Sci. 112, 1556–1566 (2021).
Wolf, J. et al. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol. 25, 1357–1370 (2024).
Mazieres, J. et al. Tepotinib treatment in patients with MET Exon 14–skipping non–small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial. JAMA Oncol. 9, 1260 (2023).
Yang, J.-J. et al. Vebreltinib for advanced non–small cell lung cancer harboring c-met exon 14 skipping mutation: a multicenter, single-arm, phase II KUNPENG study. J. Clin. Oncol. 42, 3680–3691 (2024).
Yu, Y. et al. Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial. eClinicalMedicine 59, 101952 (2023).
Lu, S. et al. Long-term efficacy, safety, and subgroup analysis of savolitinib in Chinese patients with NSCLCs harboring MET exon 14 skipping alterations. JTO Clin. Res. Rep. 3, 100407 (2022).
Xia, Y. et al. Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trial. EClinicalMedicine 81, 103099 (2025).
Drilon, A. et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat. Med. 26, 47–51 (2020).
Kim, D.-W., Lee, S.-H., Jang, I.-J., Park, K.-J. & Lee, D. H. 998P A phase I study of CKD-702, an EGFR-cMET bispecific antibody, in advanced or metastatic non-small cell lung cancer (NSCLC). Ann. Oncol. 33, S1010 (2022).
Cho, B. C. et al. 1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study. Ann. Oncol. 33, S1085 (2022).
Camidge, D. R. et al. Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆). J. Clin. Oncol. 38, 9510 (2020).
Remon, J. MET alterations in NSCLC-current perspectives and future challenges. J. Thorac. Oncol. 18, 419–435 (2022).
Han, Y. et al. Targeting MET in NSCLC: an ever-expanding territory. JTO Clin. Res. Rep. 5, 100630 (2024).
Guo, R. et al. MET-dependent solid tumours—molecular diagnosis and targeted therapy. Nat. Rev. Clin. Oncol. 17, 569–587 (2020).
Camidge, D. R. et al. Crizotinib in patients with MET-amplified NSCLC. J. Thorac. Oncol. 16, 1017–1029 (2021).
Le, X. et al. Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B. Cell Rep. Med. 4, 101280 (2023).
Majeed, U., Manochakian, R., Zhao, Y. & Lou, Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J. Hematol. Oncol. 14, 108 (2021).
Yu, Y. et al. A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib. Ther. Adv. Med. Oncol. 16, 17588359241264730 (2024).
Camidge, D. R. et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein–overexpressing advanced nonsquamous EGFR -wildtype non–small cell lung cancer in the phase II LUMINOSITY trial. J. Clin. Oncol. 42, 3000–3011 (2024).
Pereira, F. et al. KRAS as a modulator of the inflammatory tumor microenvironment: therapeutic implications. Cells 11, 398 (2022).
Sacher, A. et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N. Engl. J. Med. 389, 710–721 (2023).
Cui, W. et al. Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. Lung Cancer 146, 310–317 (2020).
Dy, G. K. et al. Long-Term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non–small-cell lung cancer: 2-year analysis of CodeBreaK 100. J. Clin. Oncol. 41, 3311–3317 (2023).
de Langen, A. J. et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet 401, 733–746 (2023).
Gadgeel, S. et al. MA06.04 KRYSTAL-1: two-year follow-up of adagrasib (MRTX849) monotherapy in patients with advanced/metastatic KRASG12C-mutated NSCLC. J. Thorac. Oncol. 18, S118 (2023).
Barlesi, F. et al. Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. Lancet 406, 615–626 (2025).
Zhou, Q. et al. Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced NSCLC: results from a phase 2 pivotal study. J. Thorac. Oncol. 19, 1630–1639 (2024).
Shi, Y. et al. Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial. Nat. Med. 31, 894–900 (2025).
Li, Z. et al. Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial. Lancet Respir. Med. 12, 589–598 (2024).
Zhong, J. et al. Sosimerasib monotherapy in patients with previously treated KRAS G12C–mutated non-small cell lung cancer: Primary results of a phase 2 study. J. Clin. Oncol. 43, 8520 (2025).
Heist, R. S. et al. Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors. J. Clin. Oncol. 42, 3007 (2024).
Li, B. T. et al. Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: updated analysis from the international CodeBreaK 101 trial. J. Clin. Oncol. 42, 8512 (2024).
Akamatsu, H. et al. A single-arm phase 2 study of sotorasib plus carboplatin and pemetrexed in patients with advanced nonsquamous NSCLC with KRAS G12C mutation (WJOG14821L, SCARLET). J. Thorac. Oncol. 20, 775–785 (2025).
Molina-Arcas, M. & Downward, J. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity. Cancer Cell 42, 338–357 (2024).
Li, B. T. et al. OA03.06 CodeBreaK 100/101: first report of safety/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC. J. Thorac. Oncol. 17, S10–S11 (2022).
Janne, P. A. First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study. J. Clin. Oncol. 43, 8500–8500 (2025).
Dragnev, K. H. et al. Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: update from the LOXO-RAS-20001 trial. J. Clin. Oncol. 43, 8519 (2025).
Gregorc, V. et al. KROCUS: a phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC. J. Clin. Oncol. 42, LBA8511 (2024).
Liermann, J. Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: long-term results of the randomized controlled phase II PARC trial. Clin. Transl. Radiat. Oncol. 34, 15–22 (2022).
Wang, M. et al. Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation. J. Immunother. Cancer 10, e004095 (2022).
Planchard, D. et al. Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis. J. Thorac. Oncol. 17, 103–115 (2022).
Planchard, D. et al. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 17, 984–993 (2016).
Planchard, D. et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 18, 1307–1316 (2017).
Riely, G. J. et al. Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600 -mutant metastatic non–small-cell lung cancer. J. Clin. Oncol. 41, 3700–3711 (2023).
Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373, 726–736 (2015).
Subbiah, V. et al. Efficacy of vemurafenib in patients with non–small-cell lung cancer with BRAF V600 mutation: an open-label, single-arm cohort of the histology-independent VE-BASKET study. JCO Precis. Oncol. 3, 1–9 (2019).
Janku, F. et al. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. Eur. J. Cancer 196, 113458 (2024).
McLoughlin, E. M., Fadul, C. E., Patel, S. H., Hall, R. D. & Gentzler, R. D. Clinical and radiographic response of leptomeningeal and brain metastases to encorafenib and binimetinib in a patient with BRAF V600E-mutated lung adenocarcinoma. J. Thorac. Oncol. 14, e269–e271 (2019).
Meng, Y. et al. Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report. Ann. Transl. Med. 10, 496–496 (2022).
Subbiah, V. et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann. Oncol. 29, 1869–1876 (2018).
Li, W. et al. First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors. Signal Transduct. Target. Ther. 9, 300 (2024).
Drilon, A. et al. Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET–rearranged lung cancers. J. Thorac. Oncol. 13, 1595–1601 (2018).
Griesinger, F. et al. Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann. Oncol. 33, 1168–1178 (2022).
Gautschi, O. 35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer. ESMO Open 9, 102614 (2024).
Zhou, C. et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion–positive NSCLC. N. Engl. J. Med. 389, 1839–1850 (2023).
Subbiah, V. et al. Intracranial efficacy of selpercatinib in RET fusion-positive non–small cell lung cancers on the LIBRETTO-001 trial. Clin. Cancer Res. 27, 4160–4167 (2021).
Tsui, D. C. C. et al. Central nervous system response to selpercartinib in patient with RET-rearranged non-small cell lung cancer after developing leptomeningeal disease on pralsetinib. Clin. Lung Cancer 23, e5–e8 (2022).
Zhou, Q. et al. A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. J. Clin. Oncol. 41, 3007 (2023).
Lu, S. et al. Abstract CT201: HS-10365, a highly potent and selective RET tyrosine kinase inhibitor, demonstrates robust activity in RET fusion positive NSCLC patients. Cancer Res. 83, CT201 (2023).
Drilon, A. et al. Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 17, 1653–1660 (2016).
Felip, E. et al. Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: results of the ETOP ALERT-lung trial. Lung Cancer 172, 94–99 (2022).
Girard, N. et al. Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: results from an expansion cohort of the SOHO-01 phase I/II study. J. Clin. Oncol. 42, LBA8598 (2024).
Nützinger, J. et al. Management of HER2 alterations in non-small cell lung cancer—the past, present, and future. Lung Cancer 186, 107385 (2023).
Zhang, X. et al. Novel development strategies and challenges for anti-HER2 antibody-drug conjugates. Antib. Ther. 5, 18–29 (2022).
Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct. Target. Ther. 7, 93 (2022).
Jacca, S. et al. Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous HER-2+ mammary cancer. OncoImmunology 5, e1082705 (2016).
Desai, A., Abdayem, P., Adjei, A. A. & Planchard, D. Antibody-drug conjugates: a promising novel therapeutic approach in lung cancer. Lung Cancer 163, 96–106 (2022).
Le, X. et al. Poziotinib in non–small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial. J. Clin. Oncol. 40, 710–718 (2022).
Cornelissen, R. et al. Poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: ZENITH20-4, a multicenter, multicohort, open-label, phase 2 trial (cohort 4). J. Thorac. Oncol. 18, 1031–1041 (2023).
Kris, M. G. et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann. Oncol. 26, 1421–1427 (2015).
Zhou, C. et al. Pyrotinib in HER2 -mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, phase II study. J. Clin. Oncol. 38, 2753–2761 (2020).
Dziadziuszko, R. et al. Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of european thoracic oncology platform (ETOP). J. Thorac. Oncol. 14, 1086–1094 (2019).
Loong, H. H. et al. SOHO-01: safety and efficacy of BAY 2927088 in patients with advanced HER2- mutant non-small cell lung cancer (NSCLC) who were pretreated but na¨ıve to HER2- targeted therapy or had not received any treatment for advanced disease. J. Clin. Oncol. 43, 8504 (2025).
Heymach, J. et al. Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data. J. Clin. Oncol. 41, 8545 (2023).
Yamamoto, N. et al. LBA5 Zongertinib in patients with HER2-mutant NSCLC: updated analysis of beamion LUNG-1. Ann. Oncol. 35, S1623–S1624 (2024).
Mazieres, J. et al. Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced non–small-cell lung cancer harboring HER2 mutations: results from the IFCT-1703 R2D2 trial. J. Clin. Oncol. 40, 719–728 (2022).
Jänne, P. A. et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02—a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC. J. Thorac. Oncol. 20, 1814–1828 (2025).
Yang, Y. et al. Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations. J. Clin. Oncol. 43, 3001 (2025).
Li, B. T. et al. Ado-trastuzumab emtansine for patients with HER2 -mutant lung cancers: results from a phase II basket trial. J. Clin. Oncol. 36, 2532–2537 (2018).
Yao, H. et al. Safety, efficacy, and pharmacokinetics of SHR-A1811, a human epidermal growth factor receptor 2–directed antibody-drug conjugate, in human epidermal growth factor receptor 2–expressing or mutated advanced solid tumors: a global phase I trial. J. Clin. Oncol. 42, 3453–3465 (2024).
Solomon, J. P., Benayed, R., Hechtman, J. F. & Ladanyi, M. Identifying patients with NTRK fusion cancer. Ann. Oncol. 30, viii16–viii22 (2019).
Amatu, A. et al. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann. Oncol. 30, viii5–viii15 (2019).
Hong, D. S. et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 21, 531–540 (2020).
Drilon, A. et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N. Engl. J. Med. 378, 731–739 (2018).
Drilon, A. et al. Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion–positive lung cancers. JCO Precis. Oncol. 6, e2100418 (2022).
Drilon, A. E. et al. Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer. J. Clin. Oncol. 42, 8570 (2024).
Rosen, E. Y. et al. Larotrectinib demonstrates CNS efficacy in TRK fusion-positive solid tumors. JCO Precis. Oncol. 3, PO.19.00009 (2019).
Doz, F. et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-Oncol. 24, 997–1007 (2022).
Cho, B. C. et al. Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC). J. Clin. Oncol. 41, 9047 (2023).
Menichincheri, M. et al. Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor. J. Med. Chem. 59, 3392–3408 (2016).
Doebele, R. C. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 21, 271–282 (2020).
Harada, G., Santini, F. C., Wilhelm, C. & Drilon, A. NTRK fusions in lung cancer: from biology to therapy. Lung Cancer 161, 108–113 (2021).
Drilon, A. et al. Repotrectinib in ROS1 fusion-positive non-small cell lung cancer. N. Engl. J. Med. 390, 118–131 (2024).
Roa, P. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents. Br. J. Cancer 131, 601–610 (2024).
Drilon, A. et al. Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers. Cancer Discov. 8, 686–695 (2018).
Nagasaka, M. & Ou, S.-H. I. Neuregulin 1 fusion–positive NSCLC. J. Thorac. Oncol. 14, 1354–1359 (2019).
Gay, N. D. et al. Durable response to afatinib in lung adenocarcinoma harboring NRG1 gene fusions. J. Thorac. Oncol. 12, e107–e110 (2017).
Jones, M. R. et al. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Ann. Oncol. 28, 3092–3097 (2017).
Gan, H. K. et al. A phase I, first-in-human study of GSK2849330, an anti-HER3 monoclonal antibody, in HER3-expressing solid tumors. Oncologist 26, e1844–e1853 (2021).
Schram, A. M. et al. Efficacy of zenocutuzumab in NRG1 fusion–positive cancer. N. Engl. J. Med. 392, 566–576 (2025).
Hsu, F. et al. EGFR mutation status on brain metastases from non-small cell lung cancer. Lung Cancer 96, 101–107 (2016).
Guan, J. et al. EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan. Med. Oncol. 33, 1 (2016).
Chen, G. et al. A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK -positive non-small-cell lung cancer. Cancer Med. 6, 953–961 (2017).
Mendoza, D. P. et al. Imaging features and metastatic patterns of advanced ALK -rearranged non–small cell lung cancer. Am. J. Roentgenol. 214, 766–774 (2020).
Zhang, B. et al. JMJD8 promotes malignant progression of lung cancer by maintaining EGFR stability and EGFR/PI3K/AKT pathway activation. J. Cancer 12, 976–987 (2021).
Tsai, M.-F. et al. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. Sci. Rep. 5, 13574 (2015).
Abdel-Hamid, N. M. & Abass, S. A. Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting. Mol. Biol. Rep. 48, 6525–6538 (2021).
Matuszczak, E. et al. Levels of selected matrix metalloproteinases—MMP-1, MMP-2 and fibronectin in the saliva of patients planned for endodontic treatment or surgical extraction. J. Clin. Med. 9, 3971 (2020).
Osude, C. et al. Mediating EGFR-TKI resistance by VEGF/VEGFR autocrine pathway in non-small cell lung cancer. Cells 11, 1694 (2022).
Chen, N. et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J. Thorac. Oncol. 10, 910–923 (2015).
Chao, Y.-C. et al. Melatonin downregulates PD-L1 expression and modulates tumor immunity in KRAS-mutant non-small cell lung cancer. Int. J. Mol. Sci. 22, 5649 (2021).
Kim, S.-J. et al. Alterations in PD-L1 expression associated with acquisition of resistance to ALK Inhibitors in ALK-rearranged lung cancer. Cancer Res. Treat. 51, 1231–1240 (2019).
Tu, E. et al. Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC. JCI Insight 7, e142843 (2022).
Matthews, H. K., Bertoli, C. & De Bruin, R. A. M. Cell cycle control in cancer. Nat. Rev. Mol. Cell Biol. 23, 74–88 (2022).
Cheung, A. H. et al. Out of the cycle: impact of cell cycle aberrations on cancer metabolism and metastasis. Int. J. Cancer 152, 1510–1525 (2023).
Du, R. et al. TGIF2 promotes the progression of lung adenocarcinoma by bridging EGFR/RAS/ERK signaling to cancer cell stemness. Signal Transduct. Target. Ther. 4, 60 (2019).
Dong, Z.-Y. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. OncoImmunology 6, e1356145 (2017).
Lin, A., Wei, T., Meng, H., Luo, P. & Zhang, J. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol. Cancer 18, 139 (2019).
Yang, L. et al. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma. J. ImmunoTher. Cancer 10, e003534 (2022).
Hu, L.-Y. EGFR oncogenic mutations in NSCLC impair macrophage phagocytosis and mediate innate immune evasion through up-regulation of CD47. J. Thorac. Oncol. 19, 1186–1200 (2024).
Sereno, M., Hernandez De Córdoba, I., Gutiérrez-Gutiérrez, G. & Casado, E. Brain metastases and lung cancer: molecular biology, natural history, prediction of response and efficacy of immunotherapy. Front. Immunol. 14, 1297988 (2024).
Tiong, T.-Y. et al. Exosomal miR-21 determines lung-to-brain metastasis specificity through the DGKB/ERK axis within the tumor microenvironment. Life Sci. 329, 121945 (2023).
Shih, D. J. H. et al. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat. Genet. 52, 371–377 (2020).
Li, H. et al. E2F1-mediated repression of WNT5A expression promotes brain metastasis dependent on the ERK1/2 pathway in EGFR-mutant non-small cell lung cancer. Cell. Mol. Life Sci. 78, 2877–2891 (2021).
Breindel, J. L. et al. EGF receptor activates MET through MAPK to enhance non–small cell lung carcinoma invasion and brain metastasis. Cancer Res. 73, 5053–5065 (2013).
Biswas, A. K. et al. Targeting S100A9–ALDH1A1–retinoic acid signaling to suppress brain relapse in EGFR-mutant lung cancer. Cancer Discov. 12, 1002–1021 (2022).
Subramaniyan Parimalam, S., Badilescu, S., Sonenberg, N., Bhat, R. & Packirisamy, M. Lab-on-a-chip for the development of pro-/anti-angiogenic nanomedicines to treat brain diseases. Int. J. Mol. Sci. 20, 6126 (2019).
Xiao, G. et al. Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma. J. ImmunoTher. Cancer 11, e006243 (2023).
Furugaki, K. et al. Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292. Clin. Exp. Metastasis 28, 649–659 (2011).
Oh, T.-I. et al. PGC1α loss promotes lung cancer metastasis through epithelial-mesenchymal transition. Cancers 13, 1772 (2021).
Robichaux, J. P. et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat. Med. 24, 638–646 (2018).
Liu, S., Yu, J., Zhang, H. & Liu, J. TP53 co-mutations in advanced EGFR-mutated non–small cell lung cancer: prognosis and therapeutic strategy for cancer therapy. Front. Oncol. 12, 860563 (2022).
Pao, W. & Chmielecki, J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10, 760–774 (2010).
Ng, K. P. et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 18, 521–528 (2012).
Qin, Q. et al. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC). Thorac. Cancer 11, 2389–2397 (2020).
Volta, F. et al. Intrinsic resistance to osimertinib in EGFR mutated NSCLC cell lines induced by alteration in cell-cycle regulators. Target. Oncol. 18, 953–964 (2023).
Sharma, G. G. et al. A compound L1196M/G1202R ALK mutation in a patient with ALK-positive lung cancer with acquired resistance to brigatinib also confers primary resistance to lorlatinib. J. Thorac. Oncol. 14, e257–e259 (2019).
Wu, L. et al. Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs. J. Transl. Med. 22, 585 (2024).
Siringo, M. Co-Occurrence of ALK rearrangement and KRAS G12C mutation in NSCLC: report of two cases. Curr. Probl. Cancer 14, 100291 (2024).
Urbanska, E. M. et al. ALK-tyrosine kinase inhibitor intrinsic resistance due to de novo MET-amplification in metastatic ALK-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination—case report. Transl. Lung Cancer Res. 13, 2453–2462 (2024).
Lara-Mejía, L. et al. Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged NSCLC. J. Thorac. Oncol. 19, 119–129 (2024).
Drilon, A. et al. ROS1-dependent cancers—biology, diagnostics and therapeutics. Nat. Rev. Clin. Oncol. 18, 35–55 (2021).
Wiesweg, M. et al. High prevalence of concomitant oncogene mutations in prospectively identified patients with ROS1-positive metastatic lung cancer. J. Thorac. Oncol. 12, 54–64 (2017).
Jamme, P. et al. Alterations in the PI3K pathway drive resistance to MET inhibitors in NSCLC harboring MET exon 14 skipping mutations. J. Thorac. Oncol. 15, 741–751 (2020).
Suzawa, K. et al. Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer. Clin. Cancer Res. 25, 1248–1260 (2019).
Rotow, J. K. et al. Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer. Clin. Cancer Res. 26, 439–449 (2020).
Rotow, J. Understanding and targeting resistance mechanisms in NSCLC. Nat. Rev. Cancer 17, 637–658 (2017).
Wang, Y. et al. Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy. Quant. Imaging Med. Surg. 13, 5362–5368 (2023).
Tan, C.-S. et al. Third generation EGFR TKIs: current data and future directions. Mol. Cancer 17, 29 (2018).
Nie, L. et al. Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells. Am. J. Cancer Res. 13, 1209–1239 (2023).
Sun, Y. et al. Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization. eBioMedicine 83, 104200 (2022).
Passaro, A., Jänne, P. A., Mok, T. & Peters, S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat. Cancer 2, 377–391 (2021).
Starrett, J. H., Guernet, A. A., Cuomo, M. E. & Poels, K. E. Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations. Cancer Res. 80, 2017–2030 (2020).
Tumbrink, H. L., Heimsoeth, A. & Sos, M. L. The next tier of EGFR resistance mutations in lung cancer. Oncogene 40, 1–11 (2021).
Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
Offin, M. et al. Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-mutant lung cancers. JCO Precis. Oncol. 2, 1–12 (2018).
Schrock, A. B. et al. Receptor tyrosine kinase fusions and braf kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors. J. Thorac. Oncol. 13, 1312–1323 (2018).
Ou, S.-H. I. et al. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. Lung Cancer 111, 61–64 (2023).
Jakobsen, K. R. et al. MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells. Oncogenesis 6, e307 (2017).
Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44, 852–860 (2013).
Manabe, T. et al. IGF2 autocrine-mediated IGF1R activation is a clinically relevant mechanism of osimertinib resistance in lung cancer. Mol. Cancer Res. 18, 549–559 (2020).
Yamaoka, T., Tsurutani, J., Sagara, H. & Ohmori, T. HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer. Transl. Lung Cancer Res. 9, 2178–2183 (2020).
Shi, P. et al. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 380, 494–504 (2016).
Kono, S. A., Marshall, M. E., Ware, K. E. & Heasley, L. E. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist. Updates 12, 95–102 (2009).
Lee, T.-G. The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR -mutated lung cancer cells. Exp. Cell Res. 430, 113722 (2023).
Nakatani, K. KRAS and EGFR amplifications mediate resistance to rociletinib and osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR. Mol. Cancer Ther. 18, 112–126 (2019).
Sato, H. et al. SRC family kinase inhibition targets YES1 and YAP1 as primary drivers of lung cancer and as mediators of acquired resistance to ALK and epidermal growth factor receptor Inhibitors. JCO Precis. Oncol. 6, e2200088 (2022).
Nelson, A. W. et al. Novel SPECC1L-MET fusion detected in circulating tumor DNA in a patient with lung adenocarcinoma following treatment with erlotinib and osimertinib. J. Thorac. Oncol. 14, e27–e29 (2019).
Zeng, L. GOPC-ROS1 rearrangement as an acquired resistance mechanism to osimertinib and responding to crizotinib combined treatments in lung adenocarcinoma. J. Thorac. Oncol. 13, e114–e116 (2018).
Yoshida, R. et al. MET-induced CD73 restrains STING-mediated immunogenicity of EGFR-mutant lung cancer. Cancer Res. 82, 4079–4092 (2022).
Hsieh, M.-S., Lin, M.-W. & Lee, Y.-H. Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy. Lung Cancer 137, 76–84 (2019).
Ahmad, A. et al. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J. Hematol. Oncol. 6, 77 (2013).
Hu, C. et al. LMNA reduced acquired resistance to erlotinib in NSCLC by reversing the epithelial–mesenchymal transition via the FGFR/MAPK/c-fos signaling pathway. Int. J. Mol. Sci. 23, 13237 (2022).
Xu, W. et al. Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib. Cell Biosci. 5, 7 (2015).
Xia, G. et al. Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report. Transl. Lung Cancer Res. 12, 637–646 (2023).
Gainor, J. F. et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 6, 1118–1133 (2016).
Wu, Q. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J. Hematol. Oncol. 15, 143 (2022).
Poei, D., Ali, S., Ye, S. & Hsu, R. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies. Cancer Drug Resist. 7, 20 (2024).
Okada, K. et al. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. EBioMedicine 41, 105–119 (2019).
Recondo, G. et al. Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer. Clin. Cancer Res. 26, 242–255 (2020).
Zhu, V. W. et al. A novel sequentially evolved EML4-ALK variant 3 G1202R/S1206Y double mutation in cis confers resistance to lorlatinib: a brief report and literature review. JTO Clin. Res. Rep. 2, 100116 (2021).
Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4, 120ra117 (2012).
Pasau, T. et al. Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma. Front. Oncol. 12, 985446 (2022).
Tabbò, F., Reale, M. L., Bironzo, P. & Scagliotti, G. V. Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won. Transl. Lung Cancer Res. 9, 2545–2556 (2020).
Pailler, E. et al. Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in ALK-rearranged non–small-cell lung cancer. Clin. Cancer Res. 25, 6671–6682 (2019).
McCoach, C. E. et al. Resistance mechanisms to targeted therapies in ROS1 + and ALK + non–small cell lung cancer. Clin. Cancer Res. 24, 3334–3347 (2018).
Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480–1486 (2014).
Zhao, Y., Yang, Y., Xu, Y., Lu, S. & Jian, H. AZD0530 sensitizes drug-resistant ALK-positive lung cancer cells by inhibiting SRC signaling. FEBS Open Bio 7, 472–476 (2017).
Levacq, D., D’Haene, N., De Wind, R., Remmelink, M. & Berghmans, T. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: a new mechanism of resistance to ALK inhibitors. Lung Cancer 102, 38–41 (2016).
Takegawa, N. et al. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib. Ann. Oncol. 27, 953–955 (2016).
Qin, Z. et al. EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation. J. Exp. Med. 221, e20232028 (2024).
Caumont, C. et al. Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma. Lung Cancer 92, 15–18 (2016).
Shen, J. et al. EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling. Cell. Signal. 92, 110264 (2022).
Yang, Y. et al. EML4-ALK G1202R and EML4-ALK L1196M mutations induce crizotinib resistance in non-small cell lung cancer cells through activating epithelial–mesenchymal transition mediated by MDM2/MEK/ERK signal axis. Cell Biol. Int. 49, 55–67 (2025).
Yang, Q. et al. SIRT1 silencing promotes EMT and Crizotinib resistance by regulating autophagy through AMPK/mTOR/S6K signaling pathway in EML4-ALK L1196M and EML4-ALK G1202R mutant non-small cell lung cancer cells. Mol. Carcinog. 63, 2133–2144 (2024).
Lin, J. J. & Shaw, A. T. Resisting resistance: targeted therapies in lung cancer. Trends Cancer 2, 350–364 (2016).
Calabrese, F. et al. Morphologic-molecular transformation of oncogene addicted non-small cell lung cancer. Int. J. Mol. Sci. 23, 4164 (2022).
Lin, J. J. et al. Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion–positive lung cancer. Clin. Cancer Res. 27, 2899–2909 (2021).
Roys, A. et al. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer. Cancer Chemother. Pharm. 84, 679–688 (2019).
Priest, K. et al. Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway. npj Precis. Oncol 7, 9 (2023).
Kondo, N. et al. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF. JCI Insight 8, e173688 (2023).
Schneider, J. L. et al. Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution. npj Precis. Oncol. 7, 116 (2023).
Li, D. et al. Combined lorlatinib, dabrafenib, and trametinib treatment for ROS1-rearranged advanced non-small-cell lung cancer with a lorlatinib-induced BRAF V600E mutation: a case report. Cancer Manag. Res. 14, 3175–3179 (2022).
Dziadziuszko, R. et al. An activating KIT mutation induces crizotinib resistance in ROS1 positive lung cancer. J. Thorac. Oncol. 11, 1273–1281 (2016).
Xu, C. et al. Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: a case report and literature review. Thorac. Cancer 8, 714–719 (2017).
Lin, J. J. Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. npj Precis. Oncol 4, 21 (2020).
Lin, L. et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc. Natl. Acad. Sci. 111, E748–E757 (2014).
Facchinetti, F. et al. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer. Eur. J. Cancer 132, 211–223 (2020).
Niemantsverdriet, M. et al. KRAS mutation as a resistance mechanism to BRAF/MEK Inhibition in NSCLC. J. Thorac. Oncol. 13, e249–e251 (2018).
Rudin, C. M., Hong, K. & Streit, M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small cell lung cancer. J. Thorac. Oncol. 8, e41–e42 (2013).
Abravanel, D. L., Nishino, M., Sholl, L. M., Ambrogio, C. & Awad, M. M. An acquired NRAS Q61K mutation in BRAF V600E-mutant lung adenocarcinoma resistant to dabrafenib plus trametinib. J. Thorac. Oncol. 13, e131–e133 (2018).
Wang, V. E. et al. Adaptive resistance to dual BRAF/MEK inhibition in BRAF-driven tumors through autocrine FGFR pathway activation. Clin. Cancer Res. 25, 7202–7217 (2019).
Yao, Y. et al. Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. Respir. Res. 24, 28 (2023).
Bahcall, M. et al. Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer. Cancer Discov. 6, 1334–1341 (2016).
Fujino, T. et al. Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro. J. Thorac. Oncol. 14, 1753–1765 (2019).
Recondo, G. et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14–mutant NSCLC. Clin. Cancer Res. 26, 2615–2625 (2020).
Bahcall, M. et al. Amplification of wild-type KRAS imparts resistance to crizotinib in MET exon 14 mutant non–small cell lung cancer. Clin. Cancer Res. 24, 5963–5976 (2018).
Lin, J. J. et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann. Oncol. 31, 1725–1733 (2020).
Solomon, B. J. et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J. Thorac. Oncol. 15, 541–549 (2020).
Nakaoku, T. A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nat. Commun. 9, 625 (2018).
Nelson-Taylor, S. K. et al. Resistance to RET-inhibition in RET-rearranged NSCLC is mediated by reactivation of RAS/MAPK signaling. Mol. Cancer Ther. 16, 1623–1633 (2017).
Vakkalagadda, C. V. & Patel, J. D. Addition of trastuzumab deruxtecan to selpercatinib in a patient with RET fusion-driven NSCLC and an acquired HER2 amplification: case report. JTO Clin. Res. Rep. 4, 100603 (2023).
Peng, Y. et al. Whole-exome sequencing explored mechanism of selpercatinib resistance in RET-rearranged lung adenocarcinoma transformation into small-cell lung cancer: a case report. BMC Pulm. Med. 23, 492 (2023).
Gazeu, A. et al. Small-cell lung cancer transformation as a mechanism of resistance to pralsetinib in RET-rearranged lung adenocarcinoma: a case report. Clin. Lung Cancer 24, 72–75 (2023).
Awad, M. M. et al. Acquired resistance to KRASG12C inhibition in cancer. N. Engl. J. Med. 384, 2382–2393 (2021).
Chour, A., Toffart, A.-C., Berton, E. & Duruisseaux, M. Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer. Front. Oncol. 14, 1328728 (2024).
Suzuki, S. et al. KRAS inhibitor resistance in MET-amplified KRAS G12C non–small cell lung cancer induced By RAS- and non–RAS-mediated cell signaling mechanisms. Clin. Cancer Res. 27, 5697–5707 (2021).
Ebi, H. Epithelial to mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant non-small cell lung cancer. Clin. Cancer Res. 26, 5962–5973 (2020).
Ryan, M. B. Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition. Clin. Cancer Res. 26, 1633–1643 (2020).
Liu, F. et al. NTRK fusion in non-small cell lung cancer: diagnosis, therapy, and TRK inhibitor resistance. Front. Oncol. 12, 864666 (2022).
Schneider, J. L., Lin, J. J. & Shaw, A. T. ALK-positive lung cancer: a moving target. Nat. Cancer 4, 330–343 (2023).
De Jager, V. D., Stigt, J. A., Niemantsverdriet, M., Ter Elst, A. & Van Der Wekken, A. J. Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib. npj Precis. Oncol. 8, 113 (2024).
Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 20, 71–88 (2019).
Wu, S.-G. & Shih, J.-Y. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer. Mol. Cancer 17, 38 (2018).
Riely, G. J. et al. NCCN Guidelines Index Table of Contents Discussion. (2025). https://nccn.medlive.cn/guide/index
Niederst, M. J. et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 21, 3924–3933 (2015).
Wu, Y.-L. et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir. Med. 8, 1132–1143 (2020).
Wu, Y.-L. et al. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Lancet Oncol. 25, 989–1002 (2024).
Hartmaier, R. J. et al. Osimertinib + Savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON. Cancer Discov. 13, 98–113 (2023).
Yu, Y. et al. 305MO SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI-resistant EGFR-mutant NSCLC harboring MET amplification. Ann. Oncol. 33, S1553 (2022).
Ahn, M. et al. EP08.02-140 MET biomarker-based preliminary efficacy analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC post-osimertinib. J. Thorac. Oncol. 17, S469–S470 (2022).
Goldman, J. W. et al. Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR -mutated non-small cell lung cancer (NSCLC). J. Clin. Oncol. 40, 9013 (2022).
Camidge, D. R. et al. Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-met protein–expressing non–small-cell lung cancer. J. Clin. Oncol. 41, 1105–1115 (2023).
Jebbink, M. et al. Trastuzumab-emtansine and osimertinib combination therapy to target HER2 bypass track resistance in EGFR mutation-positive NSCLC. JTO Clin. Res. Rep. 4, 100481 (2023).
Wei, X.-W. et al. Characteristics of and treatment strategies for advanced EGFR-mutant NSCLC with concomitant BRAF variations. JTO Clin. Res. Rep. 3, 100348 (2022).
Zeng, R. et al. EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature. Cancer Drug Resist 4, 1019–1027 (2021).
Bearz, A., De Carlo, E., Doliana, R. & Schiappacassi, M. Acquired BRAF V600E mutation as resistant mechanism after treatment with third-generation EGFR tyrosine kinase inhibitor. J. Thorac. Oncol. 12, e181–e182 (2017).
Ernst, S. M. et al. Efficacy and tolerability of osimertinib and sotorasib combination treatment for osimertinib resistance caused by KRAS G12C mutation: a report of two cases. JCO Precis. Oncol. 7, e2300451 (2023).
Xie, X. et al. Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma. J. Cancer Res. Clin. Oncol. 148, 2165–2168 (2022).
Qin, Q. et al. Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR -mutant non-small cell lung cancer. Thorac. Cancer 12, 1708–1715 (2021).
Patel, S. A. et al. IL6 mediates suppression of T- and NK-cell function in EMT-associated TKI-resistant EGFR-mutant NSCLC. Clin. Cancer Res. 29, 1292–1304 (2023).
Mok, T. S. K. et al. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation–positive non–small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses. J. Clin. Oncol. 35, 4027–4034 (2017).
Patil, T. et al. Effect of continuing osimertinib with chemotherapy in the post-progression setting on progression-free survival among patients with metastatic epidermal growth factor receptor (EGFR) positive non-small cell lung cancer. J. Clin. Oncol. 39, 9124 (2021).
Watanabe, H. et al. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers. Cancer Sci. 112, 1853–1864 (2021).
Kawashima, Y. et al. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): Overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir. Med. 10, 72–82 (2022).
Zhou, Q. et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell 39, 1279–1291.e3 (2021).
Choudhury, N. J., Young, R. J., Sellitti, M., Miller, A. & Drilon, A. Lorlatinib and bevacizumab activity in ALK- rearranged lung cancers after lorlatinib progression. JCO Precis. Oncol. 4, PO-20 (2020).
Lin, J. J. et al. Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study. ESMO Open 7, 100342 (2022).
Huang, Z. et al. Efficacy and safety of crizotinib plus bevacizumab in ALK/ROS-1/c-MET positive non-small cell lung cancer: an open-label, single-arm, prospective observational study. Am. J. Transl. Res. 13, 1526–1534 (2021).
Wu, T.-C. & Lin, C.-C. Antiangiogenesis may not be a universal booster of EGFR tyrosine kinase inhibitors. J. Thorac. Oncol. 17, 1063–1066 (2022).
Zhou, T. et al. Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study. BMC Cancer 23, 333 (2023).
Lei, T. et al. Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis. Pharmacol. Res. 188, 106668 (2023).
Li, T. et al. Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo. Transl. Lung Cancer Res. 10, 1873–1888 (2021).
Wang, S. et al. Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC. J. Transl. Med. 20, 248 (2022).
Jiang, S. et al. The impact of anlotinib on brain metastases of non-small cell lung cancer: post hoc analysis of a phase III randomized control trial (ALTER0303). Oncologist 25, e870–e874 (2020).
Chen, L. K. et al. OA03.03 aumolertinib plus anlotinib in advanced NSCLC with brain metastasis: a single-arm, phase II study. J. Thorac. Oncol. 18, S48–S49 (2023).
Ma, Z. et al. Determination of intracellular anlotinib, osimertinib, afatinib and gefitinib accumulations in human brain microvascular endothelial cells by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 35, e8955 (2021).
Li, F., Zhu, T., Cao, B., Wang, J. & Liang, L. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Eur. J. Cancer 84, 184–192 (2017).
Yang, X. et al. Efficacy and safety of combination treatment with apatinib and osimertinib after osimertinib resistance in epidermal growth factor receptor-mutant non-small cell lung carcinoma—a retrospective analysis of a multicenter clinical study. Front. Mol. Biosci. 8, 639892 (2021).
Nogami, N. et al. IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J. Thorac. Oncol. 17, 309–323 (2022).
Bylicki, O. et al. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: a multicentre phase II open-label non-randomised study GFPC 06-2018. Eur. J. Cancer 183, 38–48 (2023).
Watanabe, S. et al. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study). Eur. J. Cancer 197, 113469 (2024).
Park, S. et al. Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR-or ALK-mutated non–small-cell lung cancer (ATTLAS, KCSG-LU19-04). J. Clin. Oncol. 42, 1241–1251 (2024).
Lu, S. et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 11, 624–636 (2023).
HARMONi-A Study Investigators et al. Ivonescimab plus chemotherapy in non–small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA 332, 561 (2024).
Jahanzeb, M. et al. Immunotherapy treatment patterns and outcomes among ALK-positive patients with non–small-cell lung cancer. Clin. Lung Cancer 22, 49–57 (2021).
Gainor, J. F. et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer (NSCLC): a retrospective analysis. Clin. Cancer Res. 22, 4585–4593 (2016).
Mazieres, J. et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann. Oncol. 30, 1321–1328 (2019).
Gadgeel, S. et al. OA09.03 pembrolizumab in combination with platinum-based chemotherapy in recurrent EGFR/ALK-positive non-small cell lung cancer (NSCLC). J. Thorac. Oncol. 16, S863 (2021).
Guisier, F. et al. Efficacy and safety of anti–PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018. J. Thorac. Oncol. 15, 628–636 (2020).
Wang, W. et al. Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: a multicenter retrospective study. Genes Chromosome Canc 61, 530–541 (2022).
Liu, Z. et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell 188, 3081–3096.e19 (2025).
Yonesaka, K. HER2-/HER3-targeting antibody—drug conjugates for treating lung and colorectal cancers resistant to EGFR inhibitors. Cancers 13, 1047 (2021).
Zhang, L. et al. Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): results from the randomized OptiTROP-Lung03 study. J. Clin. Oncol. 43, 8507 (2025).
Le, X. et al. 1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD. J. Thorac. Oncol. 20, S2–S4 (2025).
Nadal, E. et al. 124TiP: TROPION-Lung15: a phase III study of datopotamab deruxtecan (dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib. J. Thorac. Oncol. 20, S87–S88 (2025).
Mok, T. S. K. et al. Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. J. Clin. Oncol. 43, 8506 (2025).
Lisberg, A. et al. DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: preliminary results from the phase 1/2a trial. J. Clin. Oncol. 43, 3000 (2025).
Ma, Y. et al. BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 25, 901–911 (2024).
Park, K. et al. Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J. Clin. Oncol. 39, 3391–3402 (2021).
Qing, Z. et al. 22P EMB-01: An EGFR-cMET bispecific antibody, in advanced/metastatic solid tumors phase I results. Ann. Oncol. 33, S39–S40 (2022).
Kelly, K. et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non–small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J. Clin. Oncol. 33, 4007–4014 (2015).
Pennell, N. A. et al. SELECT: A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor–mutant non–small-cell lung cancer. J. Clin. Oncol. 37, 97–104 (2019).
Yue, D. et al. Updated overall survival and exploratory analysis from randomized, phase II EVAN study of erlotinib versus vinorelbine plus cisplatin adjuvant therapy in stage IIIA epidermal growth factor receptor+ non–small-cell lung cancer. J. Clin. Oncol. 40, 3912–3917 (2022).
Yue, D. et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir. Med. 6, 863–873 (2018).
Zhong, W.-Z. et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 19, 139–148 (2018).
Tada, H. et al. Randomized phase III study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage II-IIIA non–small-cell lung cancer with EGFR mutation (IMPACT). J. Clin. Oncol. 40, 231–241 (2022).
He, J. et al. Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir. Med. 9, 1021–1029 (2021).
Ou, W. et al. Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial. eClinicalMedicine 57, 101839 (2023).
Lv, C. et al. Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study). ESMO Open 8, 101565 (2023).
Li, N. et al. Adjuvant icotinib for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study. Signal Transduct. Target. Ther. 10, 273 (2025).
Herbst, R. S. et al. Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). J. Clin. Oncol. 41, LBA3 (2023).
Cheng, Y. et al. Abstract CT126: aumolertinib as adjuvant therapy in patients with stage II-IIIB EGFR-mutated NSCLC after complete tumor resection: a randomized, double-blind, placebo-controlled, phase 3 trial (ARTS). Cancer Res. 85, CT126 (2025).
Han, B. et al. 145P: Efficacy and safety of aumolertinib as adjuvant therapy in resectable stage I A NSCLC with high-risk factors and EGFR-sensitizing mutations (APPOINT). J. Thorac. Oncol. 20, S104–S105 (2025).
Neal, J. W. et al. Randomized phase II study of 3 months or 2 years of adjuvant afatinib in patients with surgically resected stage I-III EGFR-mutant non–small-cell lung cancer. JCO Precis. Oncol. 5, 325–332 (2021).
Zhong, W.-Z. et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR -mutant non–small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J. Clin. Oncol. 37, 2235–2245 (2019).
Xiong, L. et al. Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients. J. Int. Med. Res. 48, 0300060519887275 (2020).
Zhang, Y. et al. Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non–small cell lung cancer: a phase II study. J. Thorac. Cardiovasc. Surg. 161, 434–442.e2 (2021).
Chang, A. E. B. et al. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. Oncologist 29, 609–618 (2024).
Bian, D. et al. Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study. Nat. Commun. 14, 4655 (2023).
Lv, C. et al. Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): a multicenter, single-arm, open-label phase 2b trial. Lung Cancer 178, 151–156 (2023).
Blakely, C. M. et al. Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor–mutated non–small cell lung cancer: a phase II multicenter study. J. Clin. Oncol. 42, 3105–3114 (2024).
He, J. et al. Neoadjuvant osimertinib for resectable EGFR -mutated non–small cell lung cancer. J. Clin. Oncol. 43, 2875–2887 (2025).
Lee, J. M. P2.01-06 NAUTIKA1 study: preliminary efficacy and safety data with neoadjuvant alectinib in patients with stage IB-III ALK+ NSCLC. J. Thorac. Oncol. 18, S297–S298 (2023).
Leonetti, A. et al. Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316). J. Clin. Oncol. 43, 8015 (2025).
Zhang, C. et al. Induction alectinib or crizotinib for stage III NSCLC harboring ALK fusion: A study with 4-year follow-up. Chin. Med. J. 10, 1097 (2025). Online ahead of print.
Zhang, C. et al. Neoadjuvant crizotinib in resectable locally advanced non–small cell lung cancer with ALK rearrangement. J. Thorac. Oncol. 14, 726–731 (2019).
Zhong, W.-Z. et al. P3.08F.01 interim analysis of a phase 2 prospective trial of induction lorlatinib in locally advanced ALK-positive NSCLC (LORIN). J. Thorac. Oncol. 19, S337–S338 (2024).
Zhang, G. et al. Neoadjuvant and adjuvant iruplinalkib in resectable ALK or ROS1 fusion-positive, non-small cell lung cancer (NSCLC): the preliminary results of the single-arm, exploratory Neo-INFINITY study. J. Clin. Oncol. 43, e20044 (2025).
Zhang, C. et al. Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: a multicenter pooled analysis. npj Precis. Oncol. 6, 66 (2022).
Lee, Y. et al. Incorporating erlotinib or irinotecan plus cisplatin into chemoradiotherapy for stage III non-small cell lung cancer according to EGFR mutation status. Cancer Res. Treat. 49, 981–989 (2017).
Xing, L. et al. Erlotinib versus etoposide/cisplatin with radiation therapy in unresectable stage iii epidermal growth factor receptor mutation-positive non-small cell lung cancer: a multicenter, randomized, open-label, phase 2 trial. Int. J. Radiat. Oncol. Biol. Phys. 109, 1349–1358 (2021).
Bi, N. et al. 143P Efficacy and safety of aumolertinib (AUM) with radiotherapy versus concurrent chemoradiotherapy (cCRT) in the treatment of unresectable stage III EGFR-mutant NSCLC: A multicenter, randomized, open-label phase III study (ADVANCE). ESMO Open 9, 102730 (2024).
Komaki, R. et al. Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage III non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 92, 317–324 (2015).
Ramalingam, S. S. et al. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. J. Clin. Oncol. 42, LBA4 (2024).
Lee, S. Y. et al. P3.08F.06 PLATINUM trial: preliminary analysis of lazertinib therapy in locally advanced, unresectable, EGFR mutation(+) NSCLC following CCRT. J. Thorac. Oncol. 19, S340 (2024).
Yu, J. et al. PL04.13 aumolertinib maintenance after chemoradiotherapy in stage III non-small-cell lung cancer: interim results of the phase III study (POLESTAR). J. Thorac. Oncol. 19, S6–S7 (2024).
Choi, D.-H. et al. Clinical outcomes of maintenance durvalumab after definitive concurrent chemoradiotherapy in unresectable locally advanced stage III non-small cell lung cancer according to epidermal growth factor receptor and anaplastic lymphoma kinase status: Korean Cancer Study Group LU-22-18. J. Clin. Oncol. 42, 8061 (2024).
Barsouk, A. et al. Plunging into the PACIFIC: outcomes of patients with unresectable KRAS-mutated non-small cell lung cancer following definitive chemoradiation and durvalumab consolidation. Clin. Lung Cancer 25, e161–e171 (2024).
Riudavets, M. et al. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. Eur. J. Cancer 167, 142–148 (2022).
Chiou, G.-Y. et al. Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non–small cell lung cancer patients with brain metastases. J. Neurosurg. 137, 563–570 (2022).
He, Z.-Y., Li, M.-F., Lin, J.-H., Lin, D. & Lin, R.-J. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study. Cancer Manag. Res. 11, 2129–2138 (2019).
Ou, S.-H. I. et al. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation. Lung Cancer 96, 15–18 (2016).
Zhu, V. W. et al. Symptomatic CNS radiation necrosis requiring neurosurgical resection during treatment with lorlatinib in ALK-rearranged NSCLC: a report of two cases. Lung Cancer Targets Ther. 11, 13–18 (2020).
Thomas, N. J. et al. Brain metastases in EGFR- and ALK-positive NSCLC: outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation. J. Thorac. Oncol. 17, 116–129 (2022).
Vogelbaum, M. A. et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J. Clin. Oncol. 40, 492–516 (2022).
Miao, E. et al. Tyrosine kinase inhibitors with and without upfront CNS radiation for brain metastases in oncogene-driven non-small cell lung cancer (TURBO-NSCLC). J. Clin. Oncol. 42, 2019 (2024).
Arrieta, O. et al. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status. Thorac. Cancer 11, 1026–1037 (2020).
Johung, K. L. et al. A clinical model for identifying radiosensitive tumor genotypes in non–small cell lung cancer. Clin. Cancer Res. 19, 5523–5532 (2013).
Stella, G. M. et al. MET mutations are associated with aggressive and radioresistant brain metastatic non-small-cell lung cancer. Neuro Oncol. 18, 598–599 (2016).
Yu, H. A. et al. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann. Oncol. 28, 278–284 (2017).
Goldstein, I. M. et al. Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. Neuro-Oncol. Adv. 2, vdaa125 (2020).
Zheng, M.-M. et al. Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases. BMC Med. 20, 197 (2022).
Zhao, Y. et al. Co-occurring potentially actionable oncogenic drivers in non-small cell lung cancer. Front. Oncol. 11, 665484 (2021).
Peng, D. Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study. BMC Cancer 22, 1323 (2022).
Blakely, C. M. et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat. Genet. 49, 1693–1704 (2017).
Skoulidis, F. et al. Co-occurring genomic alterations define major subsets of KRAS -Mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 5, 860–877 (2015).
West, H. J. et al. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. J. ImmunoTher. Cancer 10, e003027 (2022).
Kotecha, R. et al. What drives patient outcomes in brain metastases: number, volume, or biology. J. Clin. Oncol. 35, 2071 (2017).
Schneider, J. L. et al. A phase 2 study of lorlatinib in patients with ROS1-rearranged lung cancer with brain-only progression on crizotinib. JTO Clin. Res. Rep. 3, 100347 (2022).
Imyanitov, E. N., Iyevleva, A. G. & Levchenko, E. V. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit. Rev. Oncol. Hematol. 157, 103194 (2021).
Pennell, N. A., Arcila, M. E., Gandara, D. R. & West, H. Biomarker testing for patients with advanced non–small cell lung cancer: real-world issues and tough choices. Am. Soc. Clin. Oncol. Educ. Book 39, 531–542 (2019).
Cohen, D. et al. Optimizing mutation and fusion detection in NSCLC by sequential DNA and RNA sequencing. J. Thorac. Oncol. 15, 1000–1014 (2020).
Zhao, Y. et al. Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective study. Lancet Oncol. 26, 136–146 (2025).
Dwivedi, K. et al. Enlightening the path to NSCLC biomarkers: utilizing the power of XAI-guided deep learning. Comput. Methods Prog. Biomed. 243, 107864 (2024).
Pascual, J. et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 33, 750–768 (2022).
Herbst, R. S. et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer. Nat. Med. 31, 1958–1968 (2025).
Chaudhuri, A. A., Binkley, M. S., Osmundson, E. C., Alizadeh, A. A. & Diehn, M. Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA. Semin. Radiat. Oncol. 25, 305–312 (2015).
HHS et al. Use of Circulating Tumor DNA for Curative‑Intent Solid Tumor Drug Development – Guidance for Industry. https://www.fda.gov/media/183874/download (2024).
Dong, S. et al. Circulating tumor DNA-guided de-escalation targeted therapy for advanced non−small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. 10, 932 (2024).
Dong, S. et al. Monitoring of circulating tumor DNA and indication of de-escalation adjuvant targeted therapy for EGFR-mutated NSCLC after complete resection. JTO Clin. Res. Rep. 6, 100758 (2025).
Becker, A. et al. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur. J. Cancer 47, 2603–2606 (2011).
Oh, I.-J., Ban, H.-J., Kim, K.-S. & Kim, Y.-C. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Lung Cancer 77, 121–127 (2012).
Kuiper, J. L. et al. Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment. Clin. Lung Cancer 16, 60–66 (2015).
Ichihara, E. et al. Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. Lung Cancer 132, 54–58 (2019).